Mark Alles begins his post-Celgene career on the board of a US-China biotech led by a former colleague
Antengene had Celgene written all over its brand. Its founder and CEO, Jay Mei, was the big biotech’s executive director of clinical development in hematology/oncology for eight years before launching his own startup in China with his former employer as a partner and investor. Celgene chipped into Antengene’s $120 million round last year, and just days ago, it also wooed Celgene’s China general manager to be its chief business officer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.